Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study

被引：0
|
作者：
Sabrina Wiebe
David Schnell
Raimund Külzer
Dietmar Gansser
Anne Weber
Gudrun Wallenstein
Atef Halabi
Anja Conrad
Sven Wind
机构：
[1] Boehringer Ingelheim Pharma GmbH & Co KG,Translational Medicine and Clinical Pharmacology
[2] Datamap GmbH,undefined
[3] Clinical Research Services (CRS) Kiel GmbH,undefined
来源：
European Journal of Drug Metabolism and Pharmacokinetics | 2017年 / 42卷
关键词：
Renal Impairment; Epidermal Growth Factor Receptor Mutation; Plasma Protein Binding; Severe Renal Impairment; Advanced Solid Tumour;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：461 / 469
页数：8
相关论文
共 50 条
  • [21] An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Variables of Edaravone in Subjects with Mild, Moderate, or No Renal Impairment
    Nakamaru, Yoshinobu
    Kakubari, Masae
    Yoshida, Kaori
    Akimoto, Makoto
    Kondo, Kazuoki
    CLINICAL THERAPEUTICS, 2020, 42 (09) : 1699 - 1714
  • [22] An Open-Label, Single-Dose, Parallel-Group Study of the Effects of Chronic Hepatic Impairment on the Safety and Pharmacokinetics of Desvenlafaxine
    Baird-Bellaire, Susan
    Behrle, Jessica A.
    Parker, Vernon D.
    Patat, Alain
    Paul, Jeffrey
    Nichols, Alice I.
    CLINICAL THERAPEUTICS, 2013, 35 (06) : 782 - 794
  • [23] A Phase-I, Open-Label, Single-Dose Study of the Pharmacokinetics of Buparlisib in Subjects With Mild to Severe Hepatic Impairment
    Csonka, Denes
    Hazel, Katharine
    Waldron, Edward
    Lorenzo, Sebastien
    Duval, Vincent
    Trandafir, Lucia
    Kobalava, Zhanna D.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (03): : 316 - 323
  • [24] Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group study
    Chen, Xinhui
    Cui, Xiaoming
    Pognan, Nathalie
    Quinlan, Michelle
    Kapoor, Shruti
    Rahmanzadeh, Gholamreza
    Giovannini, Monica
    Marbury, Thomas C.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (01) : 91 - 102
  • [25] Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study
    Manabu Kato
    Hitoshi Ishizuka
    Takashi Taguchi
    Kazuhito Shiosakai
    Emi Kamiyama
    Michio Sata
    Takafumi Yoshida
    Advances in Therapy, 2018, 35 : 1239 - 1250
  • [26] Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study
    Kato, Manabu
    Ishizuka, Hitoshi
    Taguchi, Takashi
    Shiosakai, Kazuhito
    Kamiyama, Emi
    Sata, Michio
    Yoshida, Takafumi
    ADVANCES IN THERAPY, 2018, 35 (08) : 1239 - 1250
  • [27] A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function
    Ermer, James
    Corcoran, Mary
    Lasseter, Kenneth
    Marbury, Thomas
    Yan, Brian
    Martin, Patrick T.
    THERAPEUTIC DRUG MONITORING, 2016, 38 (04) : 546 - 555
  • [28] Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study
    Gardin, Anne
    Dodman, Angela
    Kalluri, Sampath
    Neelakantham, Srikanth
    Tan, Xuemei
    Legangneux, Eric
    Shakeri-Nejad, Kasra
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (01) : 54 - 65
  • [29] AN OPEN-LABEL, SINGLE-DOSE STUDY OF THE PHARMACOKINETICS AND SAFETY OF INFIGRATINIB (BGJ398) IN SUBJECTS WITH MODERATE RENAL IMPAIRMENT AND IN MATCHED HEALTHY ADULTS.
    Ge, X.
    Reyes, M.
    Guptha, S.
    Atiee, G.
    Marbury, T.
    Fuentes, E.
    Roupe, K.
    Andrews, S.
    Moran, S.
    Martin, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S21 - S22
  • [30] An Open-Label Study to Evaluate the Effect of Eluxadoline on the Single-Dose Pharmacokinetics of Midazolam in Healthy Participants
    Boinpally, Ramesh
    McGeeney, Danielle
    Kaczynski, Edward
    Weissman, Darren
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (11): : 1341 - 1348
12345